Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America | Zendy

Yanink Caro-Vega | Zendy; Pablo F. Belaunzarán-Zamudio | Zendy; Brenda CrabtreeRamírez | Zendy; Bryan E. Shepherd | Zendy; Beatriz Grinsztejn | Zendy; Marcelo Wolff | Zendy; Jean W. Pape | Zendy; Denis Padgett | Zendy; Eduardo Gotuzzo | Zendy; Catherine C. McGowan | Zendy; Juan SierraMadero | Zendy

Open Access

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America

Author(s) -

Yanink Caro-Vega,

Pablo F. Belaunzarán-Zamudio,

Brenda CrabtreeRamírez,

Bryan E. Shepherd,

Beatriz Grinsztejn,

Marcelo Wolff,

Jean W. Pape,

Denis Padgett,

Eduardo Gotuzzo,

Catherine C. McGowan,

Juan SierraMadero

Publication year - 2018

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofy004

Subject(s) - efavirenz , medicine , protease inhibitor (pharmacology) , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , caribbean region , viral load , latin americans , linguistics , philosophy

Durability of firstline ART was longer with EFV than with bPIs. EFV-based regimens may continue to be the preferred firstline regimen for our region in the near future due to their high efficacy, relatively low toxicity (especially at lower doses), existence of generic formulations, and affordability for national programs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research